Lannett has entered into an agreement with a strategic alliance partner to be the exclusive U.S. distributor of Trientine Hydrochloride Capsules, 250 mg, which is the AB-rated generic equivalent to Syprine of Valeant Pharmaceuticals (now Bausch Health). Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.
"We expect to commence shipping Trientine soon and believe we will be one of only a few suppliers," said Tim Crew, chief executive officer of Lannett. "We are focused and remain on track to launch a sizeable number of products in the near term. These include internally developed as well as in-licensed products. Our ongoing goal is to add products to our growing portfolio, increasing and further diversifying our revenue base."
Trientine Hydrochloride Oral Capsules and Entacapone IR Tablets have estimated IQVIA market values of approximately $140 million and $23 million, respectively, for the 12-month period ending November 2018, although actual generic market values are expected to be lower.